BioGX expanded its BD Max molecular diagnostics platform with six CE Mark diagnosis tests for meningitis and antibiotic resistance.

The six new tests can diagnose viral meningitis HSV/VZV, bacterial meningitis NSH, bacterial meningitis ELGBS, carbapenem resistance KNO, carbapenem/colistin resistance VGM and vancomycin resistance.

With the expansion, the BD Max system now comprises eleven tests, with an additional ten planned for the second half of 2018.